The US FDA’s Center for Drug Evaluation and Research didn’t turn in just a near-record high number of new molecular entity and novel therapeutic biologic approvals in 2021. The annual approvals class also features the strongest showing by first-in-class agents in recent years.
CDER classified 27 of the 50 novel agents approved in 2021 as first-in-class in the FDA center’s annual approvals report,...






